Is the use of unrelated donor transplantation leveling off in Europe? The, 2016. ,
, European Society for Blood and Marrow Transplant activity survey report, Bone Marrow Transplant, vol.53, pp.1139-1148, 2018.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.129, pp.424-447, 2017. ,
Hematopoietic stem cell transplantation, Stem Cells Cloning, vol.3, pp.105-117, 2010. ,
How to select the best available related or unrelated donor of hematopoietic stem cells?, Haematologica, vol.101, pp.680-687, 2016. ,
Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia, Lancet, vol.1, pp.612-615, 1983. ,
Current status of haploidentical stem cell transplantation for leukemia, J Hematol Oncol, vol.1, p.27, 2008. ,
How I treat acute myeloid leukemia, Blood, vol.116, pp.3147-3156, 2010. ,
Aims of conditioning, Exp. Hematol, vol.31, pp.844-854, 2003. ,
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome, Biol. Blood Marrow Transplant, vol.12, pp.1047-1055, 2006. ,
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors, Blood, vol.104, pp.1550-1558, 2004. ,
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation, Blood, vol.102, pp.756-762, 2003. ,
Graft-versus-host disease, Lancet, vol.373, pp.1550-1561, 2009. ,
, Pathophysiology of GvHD and Other HSCT-Related Major Complications. Front Immunol, vol.8, p.79, 2017.
Relapse after allogeneic stem cell transplantation, Expert Rev Hematol, vol.3, pp.429-441, 2010. ,
Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype, Eur. J. Immunol, vol.5, pp.112-117, 1975. ,
Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses, J. Exp. Med, vol.191, pp.129-138, 2000. ,
Functional analysis of human NK cells by flow cytometry, Methods Mol. Biol, vol.612, pp.335-352, 2010. ,
CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells, Eur. J. Immunol, vol.31, pp.3121-3127, 2001. ,
The biology of human natural killer-cell subsets, Trends Immunol, vol.22, pp.633-640, 2001. ,
What is natural in natural killer cells?, Immunol. Lett, vol.107, pp.1-7, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00165603
CD57 in human natural killer cells and T-lymphocytes, Cancer Immunol. Immunother, vol.65, pp.441-452, 2016. ,
Expression of a functional c-kit receptor on a subset of natural killer cells, J. Exp. Med, vol.178, pp.1079-1084, 1993. ,
Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells, J. Immunol, vol.159, pp.694-702, 1997. ,
Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation, Eur. J. Immunol, vol.34, pp.455-460, 2004. ,
Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function, Cytometry A, vol.83, pp.702-713, 2013. ,
Regulation of mouse NK cell development and function by cytokines, Front Immunol, vol.4, p.450, 2013. ,
Activation of NK cell cytotoxicity, Mol. Immunol, vol.42, pp.501-510, 2005. ,
Natural killer cell signaling pathways, Science, vol.306, pp.1517-1519, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-00080580
, Z. NK cell-based immunotherapy for cancer. Semin. Immunol, vol.31, pp.37-54, 2017.
Cell death mechanisms induced by cytotoxic lymphocytes, Cell. Mol. Immunol, vol.6, pp.15-25, 2009. ,
CD107a as a functional marker for the identification of natural killer cell activity, J. Immunol. Methods, vol.294, pp.15-22, 2004. ,
Regulation of human NK-cell cytokine and chemokine production by target cell recognition, Blood, vol.115, pp.2167-2176, 2010. ,
Functions of natural killer cells, Nat. Immunol, vol.9, pp.503-510, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00294184
Natural killer cell-produced IFN-? and TNF-? induce target cell cytolysis through up-regulation of ICAM-1, J. Leukoc. Biol, vol.91, pp.299-309, 2012. ,
TNF-alpha induces two distinct caspase-8 activation pathways, Cell, vol.133, pp.693-703, 2008. ,
Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more, Seminars in Immunology, vol.31, pp.55-63, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01764667
Natural killer cell receptor signaling, Curr. Opin. Immunol, vol.15, pp.308-314, 2003. ,
Controlling natural killer cell responses: integration of signals for activation and inhibition, Annu. Rev. Immunol, vol.31, pp.227-258, 2013. ,
Roles of the NKG2D immunoreceptor and its ligands, Nat. Rev. Immunol, vol.3, pp.781-790, 2003. ,
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA, Science, vol.285, pp.727-729, 1999. ,
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans, J. Exp. Med, vol.206, pp.1495-1503, 2009. ,
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells, Immunity, vol.27, pp.965-974, 2007. ,
Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44, J. Immunol, vol.187, pp.5693-5702, 2011. ,
Identification of a cellular ligand for the natural cytotoxicity receptor NKp44, Blood, vol.122, pp.2935-2942, 2013. ,
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia, Blood, vol.99, pp.3661-3667, 2002. ,
Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCR dull phenotype induction, Blood, vol.109, pp.323-330, 2007. ,
NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML, Oncoimmunology, vol.6, p.1307491, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01789566
NK cells and cancer: you can teach innate cells new tricks, Nat. Rev. Cancer, vol.16, pp.7-19, 2016. ,
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule, J. Exp. Med, vol.198, pp.557-567, 2003. ,
Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011. ,
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, pp.1565-1570, 2011. ,
Cytokines in cancer pathogenesis and cancer therapy, Nat. Rev. Cancer, vol.4, pp.11-22, 2004. ,
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population, Lancet, vol.356, pp.1795-1799, 2000. ,
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity, J. Clin. Invest, vol.121, pp.3609-3622, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01765654
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells, Proc. Natl. Acad. Sci. U.S.A, vol.100, pp.4120-4125, 2003. ,
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer, Oncotarget, vol.6, pp.14360-14373, 2015. ,
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia, Blood, vol.99, pp.3661-3667, 2002. ,
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia, Oncotarget, vol.8, pp.49548-49563, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01568368
Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity, Semin. Oncol, vol.39, pp.643-652, 2012. ,
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes, Blood, vol.105, pp.4878-4884, 2005. ,
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, vol.295, pp.2097-2100, 2002. ,
Donor activating KIR2DS1 in leukemia, N. Engl. J. Med, vol.371, p.2042, 2014. ,
Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation, Blood, vol.115, pp.3162-3165, 2010. ,
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans, Semin Immunopathol, vol.30, pp.425-437, 2008. ,
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, vol.295, issue.5562, pp.2097-100, 2002. ,
Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation, Front Immunology, vol.7, p.144, 2016. ,
Reconstitution of natural killer cells in HLA-matched HSCT after reducedintensity conditioning: impact on clinical outcome, Biol Blood Marrow Transplant, pp.429-468, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01108575
Clinical relevance of natural killer cells following hematopoietic stem cell transplantation, Journal of Cancer, vol.4, issue.1, pp.25-35, 2013. ,
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol, Front Oncol, vol.3, p.118, 2013. ,
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: The force awakens, Nature Reviews Drug Discovery, vol.14, pp.487-498, 2015. ,
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy, Nat Commun, vol.7, p.12878, 2016. ,
Anticancer Cytokines: Biology and Clinical Effects of Interferon-?2, Interleukin (IL)-2, IL-15, IL-21, and IL-12, Semin. Oncol, vol.42, pp.539-548, 2015. ,
The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors, Arthritis Research and Therapy, vol.9, pp.1-15, 2007. ,
Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders, Leuk. Lymphoma, vol.1, p.10, 2019. ,
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation, Blood, vol.130, pp.1857-1868, 2017. ,
Clinical utility of natural killer cells in cancer therapy and transplantation, Semin. Immunol, vol.26, pp.161-172, 2014. ,
Observations on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Engl. J. Med, vol.313, pp.1485-1492, 1985. ,
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, vol.105, pp.3051-3057, 2005. ,
Cord Blood as a Source of Natural Killer Cells, Front Med (Lausanne), vol.2, p.93, 2015. ,
Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective, Front Immunol, vol.5, p.439, 2014. ,
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity, Cell Stem Cell, vol.23, pp.181-192, 2018. ,
Clinical-Grade mRNA Electroporation of NK Cells: A Novel and Highly Efficient Method to Genetically Reprogram Human NK Cells for Cancer Immunotherapy, Blood, vol.124, p.2153, 2014. ,
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation, Biol. Blood Marrow Transplant, vol.22, pp.705-709, 2016. ,
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients, Blood, vol.118, pp.3273-3279, 2011. ,
Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers, Cytotherapy, vol.15, pp.231-241, 2013. ,
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine', Nature, vol.484, pp.529-533, 2012. ,
Bortezomib treatment to potentiate the antitumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells, Journal of Cancer, vol.2, pp.383-385, 2011. ,
Bringing natural killer cells to the clinic: ex vivo manipulation ,
, Hematology, pp.234-246, 2013.
The Future of Immune Checkpoint 4, vol.348, 2015. ,
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells, Blood, vol.114, pp.2667-2677, 2009. ,
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C, Nature, vol.391, pp.795-799, 1998. ,
Human cytomegalovirus and natural killer-mediated surveillance of HLA class I expression: a paradigm of host-pathogen adaptation, Immunol. Rev, vol.181, pp.193-202, 2001. ,
HLA-E upregulation on IFN-?-activated AML blasts impairs CD94/ NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT, Bone Marrow Transplantation, vol.43, pp.693-699, 2009. ,
The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma, Oncotarget, vol.7, pp.3477-3488, 2016. ,
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization, Journal of Allergy and Clinical Immunology, vol.139, pp.335-346, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01788010
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo, J. Immunol, vol.194, pp.950-959, 2015. ,
Tim-3: an emerging target in the cancer immunotherapy landscape, Cancer Immunol Res, vol.2, pp.393-398, 2014. ,
Coexpression of Tim-3 and PD-1 identifies a CD8 ? T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia, Blood, vol.117, pp.4501-4510, 2013. ,
Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A KIR Haplotype, The Journal of Immunology, vol.181, pp.6010-6019, 2008. ,
The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation. Haematologica haematol, p.186619, 2017. ,
Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome, Biology of Blood and Marrow Transplantation, vol.21, pp.429-439, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01108575
NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: Immaturity of NK cells and inhibitory effect of NKG2A override GvL effect, Blood, vol.105, pp.4135-4142, 2005. ,
Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy, Journal of Clinical Immunology, vol.32, pp.632-646, 2012. ,